The Early Ophthalmic Effects of Vatinoxan in Healthy Detomidine-Sedated Horses.

Vatinoxan prevents detomidine-induced intraocular pressure reduction in horses.

This randomized, masked, crossover study evaluated vatinoxan's ophthalmic effects in seven healthy horses receiving detomidine sedation. Vatinoxan is a peripherally selective alpha2-adrenoceptor antagonist investigated for its potential to mitigate detomidine's ocular side effects. Horses received either detomidine alone (20 μg/kg IV) or detomidine with vatinoxan (200 μg/kg IV). Intraocular pressure, tear production (Schirmer tear test), and vertical pupil diameter were measured at predetermined intervals for 25 minutes post-treatment. Results demonstrated that detomidine alone significantly reduced IOP throughout the observation period, while vatinoxan co-administration prevented this IOP decrease. Tear production increased similarly with both treatments. Pupil diameter remained unchanged with either treatment. The study concludes that vatinoxan effectively alleviates the early detomidine-associated decrease in intraocular pressure in healthy horses, suggesting potential clinical benefits in mitigating detomidine's ocular effects during equine anesthesia.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.